Live Breaking News & Updates on Negative Symptoms Factor Score

Stay updated with breaking news from Negative symptoms factor score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA Denies Approval of Roluperidone for Negative Symptoms of Schizophrenia

Roluperidone is an investigational drug intended to specifically block the serotonin receptor subtype, 5-HT2A, as well as the sigma2 and adrenergic-α1A receptors. ....

Remy Luthringer , Minerva Neurosciences , Drug Administration , Complete Response Letter , New Drug Application , Negative Syndrome Scale , Negative Symptoms Factor Score , Executive Chairman ,

Minerva Neurosciences, Inc: Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

WALTHAM, Mass., Aug. 22, 2022(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the ....

United States , Helen Shik , Remy Luthringer , Frederick Ahlholm , Minerva Neurosciences , Exchange Commission , Exchange Commission On , Shik Communications , Drug Administration , Minerva Neurosciences Inc , New Drug Application , Executive Chairman , Chief Executive , Open Label , Negative Syndrome Scale , Social Performance Scale , Clinical Global Impression , Structured Model Negative , Negative Symptoms Factor Score , Double Blind , Private Securities Litigation Reform Act , Quarterly Report ,

Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

WALTHAM, Mass., Aug. 22, 2022 Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today. | August 22, 2022 ....

United States , Helen Shik , Remy Luthringer , Frederick Ahlholm , Minerva Neurosciences , Exchange Commission , Shik Communications , Drug Administration , Minerva Neurosciences Inc , Globenewswire Inc , New Drug Application , Executive Chairman , Chief Executive , Open Label , Negative Syndrome Scale , Social Performance Scale , Clinical Global Impression , Structured Model Negative , Negative Symptoms Factor Score , Double Blind , Private Securities Litigation Reform Act , Quarterly Report , Nc Stock Exchange , Press Release , Ystem Nerv Us6033802058 ,